Features of aggressive breast cancer

被引:59
作者
Arpino, Grazia [1 ]
Milano, Monica [1 ]
De Placido, Sabino [1 ]
机构
[1] Univ Naples Federico II, Naples, Italy
关键词
Breast cancer; Metastatic breast cancer; Aggressive breast cancer; Prognostic factors; Biological features; Clinical features; CIRCULATING TUMOR-CELLS; PHASE-III TRIAL; LONG-TERM SURVIVAL; PROGNOSTIC-FACTORS; PROGESTERONE-RECEPTOR; PLUS CAPECITABINE; ESTROGEN-RECEPTOR; CHEMOTHERAPY RESPONSE; MOLECULAR PORTRAITS; LINE CHEMOTHERAPY;
D O I
10.1016/j.breast.2015.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Aggressive breast cancer is a term commonly used in literature to describe breast cancer with a poor prognosis. Identifying and understanding the factors associated with aggressiveness could be helpful to the management of patients with breast cancer. Breast cancer is a heterogeneous disease, both clinically and biologically, which may be responsible for the wide range of survival durations for patients with metastatic disease. Aim: The goal of this study was to identify the factors most often described in association with aggressive metastatic breast cancer (MBC). Methods: A systematic review was performed by querying PubMed from January 1, 2012 to June 1, 2014 for "metastatic breast cancer" ("aggressive" or "poor prognosis" or "high risk"). The level of evidence to support each potential prognostic factor of aggressive MBC was also reviewed. Results: The identified factors were grouped into 3 principle categories: clinical, biological, and patient related. Because patient-related factors may not be indicative of inherent cancer aggressiveness, this review focused only on clinical and biological factors. The factors with the highest levels of evidence to support associations with survival in metastatic breast cancer were visceral metastases, number of metastatic sites, disease-free interval, presence of CTCs, triple-negative disease, and tumour grade. Conclusion: Identification of these factors and understanding their contribution to the aggressiveness of MBC and disease progression may lead to more personalized treatment in this patient population. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:594 / 600
页数:7
相关论文
共 66 条
[1]   Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer [J].
Anderson, H. ;
Hills, M. ;
Zabaglo, L. ;
A'Hern, R. ;
Leary, A. F. ;
Haynes, B. P. ;
Smith, I. E. ;
Dowsett, M. .
ANNALS OF ONCOLOGY, 2011, 22 (08) :1770-1776
[2]  
[Anonymous], NAT COMPR CANC NETW
[3]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[4]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[5]   RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].
Brufsky, Adam M. ;
Hurvitz, Sara ;
Perez, Edith ;
Swamy, Raji ;
Valero, Vicente ;
O'Neill, Vincent ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4286-4293
[6]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[7]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[8]  
2-H
[9]   Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor [J].
Chang, J ;
Clark, GM ;
Allred, DC ;
Mohsin, S ;
Chamness, G ;
Elledge, RM .
CANCER, 2003, 97 (03) :545-553
[10]   Prognostic and predictive factors in early-stage breast cancer [J].
Cianfrocca, M ;
Goldstein, LJ .
ONCOLOGIST, 2004, 9 (06) :606-616